Project Portfolio
Selected NPP work in opportunity assessment, commercial due diligence, portfolio evaluation, and evidence strategy.
Which Opportunities to Pursue
Simplifying Opportunity Selection in a Complex Rare Disease Landscape
A rare-disease assessment that gave leadership a clearer way to weigh preclinical options.
How a purpose-built database, structured client inputs, and an interpretable clustering framework helped turn a long list of preclinical disease options into a few clearly defined opportunity types.
Advance, Partner, or Acquire
Embedded Commercial Due Diligence
With capacity stretched, a practical way to assess a rare‑disease asset was needed.
A structured due diligence of a rare‑disease asset, built from the available evidence and early clinical plans, for use in governance.
Which Programs to Keep Backing
Does This Portfolio Earn Its Place?
A closer read of the available evidence showed where the portfolio’s case for continued backing was more compelling and where it was more contingent.
Bringing commercial realism to a board‑level phase II portfolio decision under tight timelines and data‑room‑only constraints.
Evidence Threshold for Follow-On Indications
Evidence Expectations as Inputs to Neurology Label‑Expansion Strategy
Potential label-expansion value needs to be weighed against likely real-world use and the development lift required to support it.
Patient journey and TPP testing clarified likely use, priority patients, and the evidence needed to support each indication.
Facing a similar decision? Let’s talk it through.